Adicet Bio Q4 net loss widens

ADICET Bio

12/03/2026 20:10

Overview

Clinical stage biotech's Q4 net loss widened yr/yr

Operating expenses for Q4 rose due to higher CRO and CDMO costs

Company raised $74.8 mln in equity. It expects cash to fund operations into 2H/2027

Outlook

Adicet expects to provide a clinical update on prula-cel in 1H/2026, with another in 2H/2026

Company plans regulatory filing for ADI-212 in 3Q/2026, with Phase 1 enrollment expected 4Q/2026

Adicet expects current cash and investments to fund operations into the second half of 2027

Result Drivers

HIGHER R&D SPENDING - Q4 R&D expenses rose due to increased costs for contract research and manufacturing organizations

LOWER G&A COSTS - Q4 general and administrative expenses fell, mainly from reduced rent, office, and professional services costs

Cash, cash equivalents and short-term investments were $158.5 million as of December 31, 2025, compared to $176.3 million as of December 31, 2024

Company press release: ID:nBw1XFlx7a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
-$30.52 mln
Q4 Basic EPS
-$2.94
Q4 Operating Expenses
$31.89 mln
Q4 Operating Income
-$31.89 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Adicet Bio Inc is $37.50, about 402% above its March 11 closing price of $7.47

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)